|
|
|
| The value of 18F-FDG PET/CT imaging in the follow-up of ovarian cancer aftersurgery and the relationship between PET/CT imaging and serum CA125 assay |
| DENG Zhi-yong1, ZHOU You-jun2, SUN Hua1, WANG Chun1, XIE Ran1, ZHAO Shen1, LI Xiao1 |
| 1.Center of PET/CT, the Third Affiliated Hospital of Kunming Medicial College, Kunming 650118, China;2.Department of Nuclear Medicine, Kunming Yanan Hospital, Kunming 650051, China |
|
|
|
|
Abstract Objective: To evaluate the value of 18F-FDG PET/CT imaging in the follow-up of ovarian cancer after surgery and the relationship between PET/CT imaging and serum CA125 assay. Methods: 18F-FDG PET/CT and serum CA125 assay were performed in 45 postoperative patients with ovarian cancer. The diagnostic value was determined according to the results of surgical pathology or clinical follow-up. Results: The sensitivity, specificity, accuracy, positive predictive value, negative predictive value of 18F-FDG PET/CT imaging for detecting ovarian cancer recurrence or metastasis were 90.3%(28/31), 92.8%(13/14), 91.1%(41/45), 96.5%(28/29) and 81.5%(13/16), respectively. And the sensitivity, specificity, accuracy, positive predictive value, negative predictive value of serum CA125 assay for detecting ovarian cancer recurrence or metastasis were 74.2%(23/31), 78.5%(11/14), 75.5%(34/45), 88.4%(23/26) and 57.9%(11/19), respectively. There was a correlation between 18F-FDG PET/CT imaging and serum CA125 assay. Among 26 patients with increased serum CA125, recurrent lesions were detected by 18F-FDG PET/CT in 23 patients. However, among 19 patients with normal CA125, only 8 patients were detected to have recurrent lesions by 18F-FDG PET/CT. The recurrence detected by 18F-FDG PET/CT was statistically different between increased serum CA125 group and normal CA125 group(χ2=11.007，P=0.001). Fewer recurrent lesions were found in 10 patients with serum CA125≤100 U/mL. In our study, 90%(9/10) of patients with serum CA125≤100 U/mL had 1~3 recurrent lesions. More than 3 recurrent lesions were found in 21 patients with serum CA125＞100 U/mL. The number of recurrent lesions was statistically different between the group with serum CA125≤100 U/mL and that with serum CA125＞100 U/mL(χ2=14.006, P=0). Conclusion: 18F-FDG PET/CT possesses an important clinical priority for following-up patients with ovarian cancer after surgery. There was a correlation between 18F-FDG PET/CT imaging and serum CA125 assay. 18F-FDG PET/CT and serum CA125 assay can complement each other.
|
|
Received: 30 May 2011
|
|
|
|
|
|
|
|
|
2012, Vol. 23 
